Insights

Guillain-Barré syndrome (GBS) in children can lead to severe outcomes. The axonal form and advanced clinical stage are poor prognostic factors for recovery in pediatric GBS patients.

Area of Science:

  • Neurology
  • Pediatrics
  • Clinical Research

Background:

  • Guillain-Barré syndrome (GBS) is a significant cause of acute polyneuropathy.
  • It can result in severe morbidity and mortality.
  • Understanding prognostic factors is crucial for patient management.

Purpose of the Study:

  • To evaluate clinical, laboratory, electrophysiological, and prognostic features of pediatric GBS.
  • To identify factors associated with poor outcomes in children with GBS.

Main Methods:

  • Retrospective analysis of 46 pediatric patients diagnosed with GBS.
  • Patients categorized into two groups based on recovery time (within 2 months vs. beyond 2 months).
  • Evaluation included clinical presentation, laboratory findings, and electrophysiological studies.

Main Results:

  • Acute inflammatory demyelinating polyradiculoneuropathy observed in 56.5% and axonal form in 43.5% of patients.
  • Antecedent events were reported in 60.9% of cases.
  • Mechanical ventilation was required for 10.8% and mortality occurred in 2.1% of patients.
  • Poor outcomes were significantly associated with the axonal electrophysiological subtype and advanced clinical stage.

Conclusions:

  • The axonal form of GBS and advanced clinical stage are identified as poor prognostic indicators in children.
  • Early identification of these factors can aid in timely intervention and management strategies.
  • Further research may focus on specific treatments targeting these subtypes for improved outcomes.

Related Concept Videos

Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...